Ebos Group Limited · NZX:EBO
Ebos — Shareholder Meeting (October 2026)
43 slides from Ebos's shareholder meeting presentation, Oct 21, 2026
Slide 1: EBOS Group Limited 2026 Annual Meeting
For personal use only 21 October 2026 NZX/ASX Code: EBO EBOS GROUP LIMITED 2026 ANNUAL MEETING Please see attached the Chair's speech, CEO's speech and presentation materials for the Annual Meeting of shareholders to be held today. Authorised for lodgement with NZX and ASX by the Board of EBOS Group
Slide 2: Chair's Address to Shareholders
Chair’s Address to Shareholders Turning now to our highlights for the year. For personal use only We will begin with a short video. The video captures the breadth of our operations, the dedication of our people and the key role we play in supporting healthcare and animal care customers and communiti
Slide 3: Chair's Address: Investment cycle and sustainability
It also marked an important milestone. Over recent years, the Board has backed a significant program of investment to modernise our network and strengthen our portfolio. That facility investment cycle is now complete. For personal use only As a result, EBOS goes into FY27 a stronger business. We hav
Slide 4: Chair's Address: Inclusive workplace and safety
We are equally committed to an inclusive and supportive workplace, because we believe that people do their best work when they feel safe, respected and valued. In FY26 we refreshed our Diversity, Equity & Inclusion Policy to ensure it aligned with that commitment and with our broader strategy. For p
Slide 5: Chair's Address: Shareholder returns
They are closely aligned with our purpose of connecting people, pets and communities to care, anywhere, and reflect the values of our employees, many of whom contribute their own time and energy to supporting local organisations and causes. For personal use only Turning now to shareholder returns, y
Slide 6: CEO's Address to Shareholders
CEO’s Address to Shareholders Thank you, Liz, and good afternoon. Thank you for joining us, whether you are here in the room or online. For personal use only I would like to cover three things this morning. First, our FY26 performance. Second, how FY27 has begun across each of our four divisions. An
Slide 7: CEO's Address: Q1 FY27 and guidance
Pleasingly, we were proactively able to mitigate some fuel costs across our various businesses. Let me now turn to the first quarter of FY27. For personal use only The key message is that positive growth has continued to build through the quarter and we are re-affirming our existing FY27 guidance, d
Slide 8: CEO's Address: Symbion & Healthcare Distribution
Obligation funding pool increased from 1 July, with earnings tracking in line with our expectations. Demand for GLP-1 and high value medicines continues to remain strong and consistent with our growth outlook. For personal use only In contract logistics, the team secured 20 new principals in FY26. A
Slide 9: CEO's Address: Retail Pharmacy Brands and Medical Technology
And fifth, owned brands. Retail sales increased at a low double-digit rate. Owned brands provide customers with good value and support stronger margins for pharmacy owners and the Group. For personal use only These levers reinforce one another. More stores create more opportunities for health servic
Slide 10: CEO's Address: Animal Care
time when household budgets remain under pressure, this performance demonstrates the strength of the brands and the trust of pet owners. The second growth engine is international expansion – particularly export of Kiwi For personal use only Kitchens to the USA. Sales of our Kiwi Kitchen product cont
Slide 11: CEO's Address: Synergies and outlook
divisions, building on the network we have just renewed. This will be a multi-year program, carefully sequenced to protect customer service, with an opportunity for proof of concept in FY27. For personal use only Together, these initiatives are expected to deliver incremental financial benefits from
Slide 12: Care, Productivity, Partnership
Care Productivity rsonal use only Partnership Annual Shareholder Meeting 2026
Slide 13: Disclaimer
Disclaimer The information in this presentation was prepared by EBOS Group Limited (“EBOS” or the “Group”) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and, to the extent permitted by law, no representation is made as to
Slide 14: Welcome
3 rsonal use only Welcome
Slide 15: How to participate in virtual/hybrid meetings and ask a question
How to participate in virtual/hybrid meetings and ask a question rsonal use only 4
Slide 16: How to participate in virtual/hybrid meetings and vote
How to participate in virtual/hybrid meetings and vote rsonal use only 5
Slide 17: Board of Directors
Board of Directors rsonal use only Elizabeth Coutts Dr Tracey Batten Mark Bloom Coline McConville Independent Chair Independent Director Independent Director Independent Director Stuart McLauchlan Matt Muscio Julie Tay Independent Director Non-executive Director Independent Director 6
Slide 18: Agenda
Agenda 1 Presentation: Elizabeth Coutts, Chair rsonal use only 2 Presentation: Adam Hall, CEO 3 Business of Meeting 4 Conclusion 7
Slide 19: Chair presentation
rsonal use only Chair presentation Elizabeth Coutts Chair
Slide 20: EBOS is a scaled Care portfolio with four divisions
EBOS is a scaled Care portfolio with 4 divisions Healthcare reporting segment Symbion & Healthcare Distribution Retail Pharmacy Brands rsonal use only ANZ’s #1 or #2 institutional healthcare Australia’s #1 community pharmacy distributor, contract logistics provider store network1, with a focus on he
Slide 21: Investment cycle complete; EBOS to continue its growth momentum
Investment cycle complete; EBOS to continue its growth momentum rsonal use only Solid growth; All FY26 guidance investment cycle metrics met complete Ongoing Balance sheet opportunities to flexibility to invest build further value in growth 10
Slide 22: EBOS has evolved into a higher-quality portfolio
EBOS has actively evolved into a higher-quality portfolio through disciplined investment, ramping up in the past six years Underlying EBITDA (A$m) rsonal use only DC renewal delivering better Care to our Accelerated growth and portfolio rebalancing Complete DC renewal customers and driving improved
Slide 23: Sustainability, community and a safe and inclusive workplace
Sustainability, community and a safe and inclusive workplace Our sustainability pillars Sustainability highlights rsonal use only • Third Climate Statement published, with refreshed climate- related risks and opportunities assessment • More rooftop solar • NZ electricity matched with renewable energ
Slide 24: Supporting health and wellbeing in our communities
Supporting health and wellbeing in our communities SELECT EXAMPLES rsonal use only Symbion & Healthcare Retail Pharmacy Medical Animal Distribution Brands Technology Care Supporting FightMND for over For 20+ years, TerryWhite Orthopeadic Outreach Donating Black Hawk kibble, 10 years, with money rais
Slide 25: Dividends
Dividends Final dividend Dividend remains supported by: rsonal use only EBOS’ Directors announced a final FY26 dividend of NZ 61.5 cents per share Strong cash flow generation Accretive returns from bolt-on investments The final dividend was fully franked for Australian taxation purposes and imputed
Slide 26: CEO presentation
rsonal use only CEO presentation Adam Hall Chief Executive Officer
Slide 27: FY26 delivered: revenue +9.9%, Underlying EBITDA +5.0%
FY26 delivered: revenue +9.9%, Underlying EBITDA +5.0%1 Guidance Revenue EBITDA NPAT rsonal use only delivered within range EBITDA2 $614m $13,487m $599m $225m Capex $145m D&A $148m 9.9% growth 7.8% growth 4.7% growth Net finance costs $119m Underlying EBITDA2 $614m Underlying NPAT $250m Leverage 2.1
Slide 28: Delivered against all FY26 financial guidance metrics
Delivered against all FY26 financial guidance metrics and Investor Day growth priorities Delivered on every financial guidance metric All FY26 guidance EBITDA Capex D&A Net finance costs Leverage rsonal use only metrics delivered $614m $145m $148m $119m 2.1x within range1 Healthcare segment Animal C
Slide 29: Positive growth building through Q1 FY27
Positive growth building through Q1 FY27 Major DC renewal program now complete, with capex of ~$145 million in FY26, expected to step down to ~$100 Step down in • FY26 saw solid million per annum in FY27 which remains on track capex unlocks growth; • Lower capital intensity driving stronger free cas
Slide 30: Symbion & Healthcare Distribution: Put capacity to work
Symbion & Healthcare Distribution: Put capacity to work New CSO regime and Kemp’s Creek productivity gains on track; CWNZ contract renewed and ramps down through FY28 HCL Perth now serving customers rsonal use only Community Pharmacy: • Contract extended, providing near-term earnings visibility for
Slide 31: Retail Pharmacy Brands: Drive store dollars
Retail Pharmacy Brands: Drive store dollars Q1 FY27 trading performance1 rsonal use only Growing the store Leading in pharmacy Accelerating online Monetising retail Growing owned network vaccinations sales media brands ~790 stores 24% +25% +35% Low double digit growth in owned brands retail TerryWhi
Slide 32: Medical Technology: Expand scope and reach
Medical Technology: Expand scope and reach CUSTOMERS 2,000 healthcare practitioners engaged in our professional rsonal use only education initiatives per annum >4,500 hospitals and clinics served Access to world class technology #1 independent distributor in ANZ1 #1 independent distributor in SEA1 L
Slide 33: Animal Care: New product and customer momentum
Animal Care: New product and customer momentum Branded portfolio excelling in International presence continues to scale challenging market rsonal use only Mid-high single digit revenue growth1 Across Black Hawk & VitaPet Kiwi Kitchens now ranged in California Outpacing the category through continued
Slide 34: Three programs of cross divisional synergy in motion
Based on a shared purpose, three programs of cross divisional synergy in motion • Reshaping teams to uplift capability and align capacity Support Underway rsonal use only office • Standardise, centralise, automate and partner From FY27 optimisation • Small run-rate benefits by end of FY27 Purpose an
Slide 35: FY27 guidance re-affirmed, with growth weighted to the second half
FY27 guidance re-affirmed, with growth weighted to the second half Execution of divisional priorities underway…. …supporting existing FY27 guidance rsonal use only Symbion & Healthcare Distribution: “Put capacity to work” $635-655m EBITDA1 mid-single-digit organic EBITDA growth Retail Pharmacy Brand
Slide 36: Our proof points
Our proof points Strong positions with structural advantages The EBOS ~85% of our Group EBITDA is from EBOS has leading positions in essential care markets, leveraged to value story favourable structural tailwinds, underpinned by scale-driven businesses in #1 or #2 positions productivity and advanta
Slide 37: Business of meeting
rsonal use only Business of meeting
Slide 38: Item 1: Annual Report and Financial Statements
Item 1: Annual Report and Financial Statements To consider and receive the annual report and the financial rsonal use only statements for the year ended 30 June 2026 and the audit report thereon 27
Slide 39: Resolution – Re-election of Director: Julie Tay
Item 2 Resolution 1 – Re-election of Director: Julie Tay rsonal use only Ms Julie Tay was appointed to the EBOS Group Limited Board in May 2023. Julie is currently a director of Sonova, a global hearing care solutions company, headquartered in Switzerland and listed on the Swiss stock exchange. She
Slide 40: Resolution – Auditor's remuneration
Item 3 Resolution 2 – Auditor’s remuneration rsonal use only It is resolved that the directors of the Company be authorised to fix the fees and expenses of Deloitte as auditor of the Company. Deloitte is automatically reappointed as the auditor of the Company under section 207T of the Companies Act
Slide 41: Any other business
Item 4 To consider any other business that can be properly brought before the meeting rsonal use only 30
Slide 42: Conclusion
me BOS only qFonclusion ersonal us
Slide 43: rsonal use only
==EBOS GROUP LIMITED